Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE PROPIONATE versus TESULOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE PROPIONATE versus TESULOID.
TESTOSTERONE PROPIONATE vs TESULOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone propionate is a short-acting androgen receptor agonist. It binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Tesuloid is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), thereby reducing pro-inflammatory cytokine production and immune-mediated inflammation.
50-400 mg intramuscularly every 2-4 weeks. For androgen replacement, 50-100 mg IM every 2 weeks.
Intravenous infusion of 500 mg over 60 minutes every 2 weeks.
None Documented
None Documented
Terminal half-life: 0.8–1.2 hours (rapid elimination due to short ester chain; requires frequent dosing).
Clinical Note
moderateTestosterone propionate + Tranylcypromine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Tranylcypromine."
Clinical Note
moderateTestosterone propionate + Procarbazine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Procarbazine."
Clinical Note
moderateTestosterone propionate + Pirlindole
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Pirlindole."
Clinical Note
moderate16–20 hours in healthy adults; prolonged to 30–40 hours in moderate renal impairment (CrCl <50 mL/min); clinically significant accumulation risk in renal disease.
Renal: 90% (as glucuronide and sulfate conjugates); Fecal/Biliary: 10%.
Primarily renal excretion (85% unchanged, 10% as glucuronide conjugate); 5% fecal.
Category D/X
Category C
Androgen
Androgen
Testosterone propionate + Moclobemide
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Moclobemide."